Breast Cancer Res Treat. 2014 Feb;143(3):587-92. doi: 10.1007/s10549-013-2831-4. Epub 2014 Jan 21.

Drukker C.A., van Tinteren H., Schmidt M.K., Rutgers E.J., Bernards R., van de Vijver M.J., Van’t Veer L.J.

MammaPrint showed a significant absolute difference in DMFS and OS at 25 years between the patients with a low-risk 70-gene signature (60.4 and 57.3 % respectively) and the patients with a high-risk 70-gene signature (41.6 and 44.5 % respectively).

Read more: Drukker et al_2014_Breast Cancer Research and Treatment_Long-Term Impact of the 70-Gene…